Podcast Index
Explora podcasts por categoría, abre episodios recientes y descarga audio para escucharlo sin conexión.
Smart Biotech Scientist | The CMC and Bioprocessing Podcast for Process Development and Manufacturing Leaders
David Brühlmann - CMC Development Leader, Bioprocess Expert, Business Strategist
Podcast Answers
Lehman Creations LLC
The Movie Rubric
The Movie Rubric
Timmyboy Comedy Podcast
Tim & Jolynn & Littleman
Ciro Gómez Leyva por la Mañana
Radio Fórmula
The Archers
BBC Radio 4
Steelers Podcast - The Terrible Podcast
The Terrible Podcast
Stugotz and Company
iHeartPodcasts
Autoblog News
The Jacob Shapiro Podcast
Jacob Shapiro
The Moscow Murders and More
Bobby Capucci
Karsch and Anderson
Audacy
Clydesdale Media Podcast
Scott Switzer
Gun Talk
Gun Talk Media
The Sports Agents
Global
Tabletop Tangents
Tracy Sizemore, Dot Moore, Chris Hussey
Bloomberg News Now
Samejo
Flash Stock Reports (Video)
Flash by StockSentinel.AI
Klein/Ally Show: The Podcast
Audacy
Radio 1370AM Peligrosa.mx Tlax/Pue
grupo informativo 1370AM sa de cv
Better Together
United Volleyball
Tri-State Hockey Podcast
The Nation Network
Charlotte News Today | 2 Min News | The Daily News Now!
The Daily News Now!
Dave And Molly Show
NonStop Local
Jesus 911
Jesse Romero, Eddie Chavez, Ruben Nava
Daily Tech News Show
Tom Merritt
JIM WEBB PODCAST
Produced and Distributed by OMG Media Partners, LLC.
گفتوگوی ویژه - Special Interview
ایران اینترنشنال
L'Aria che Tira - Pillole di Lirica
Ameria Radio
Seattle News Today | 2 Min News | The Daily News Now!
The Daily News Now!
The F1 Show
Sky Sports
Auckland News Today | 2 Min News | The Daily News Now!
The Daily News Now!
Hypnosis for sleeping deeply (Jason Newland)
Jason Newland
RealClearPolitics Podcast
RealClearPolitics, Carl Cannon, Tom Bevan
The Great Shalom Podcast : Overcoming Learning Problems
Sharon Sarles
Universo de Misterios
Universo de Misterios
WagerTalk: Sports Betting Tips
WagerTalk Media
Todo
David Brühlmann - CMC Development Leader, Bioprocess Expert, Business Strategist
The cell and gene therapy industry faces massive hurdles—cost, scalability, and the need for highly skilled operators have historically limited the reach of these transformative treatments. advanced therapy medicinal pro...
What if the simple act of opening an incubator could undermine the consistency of your cell therapy manufacturing process? Unlike traditional biologics, the moment cells leave their incubator, subtle shifts in temperatur...
Digital transformation in biotech is no longer just about adopting new tools, it's about building a foundation where automation, data standardization, and AI integration actually lead to real value and long-term success....
Despite cutting-edge equipment and brilliant minds, biotech labs often find half their data trapped in difficult-to-access spreadsheets or isolated in silos, making true digital transformation a major, industry-wide hurd...
Host David Brühlmann returns for a focused solo episode to provide an honest, data-driven perspective on the evolving landscape of host selection for biologics manufacturing. Building on part one, David reviews five alte...
In this solo episode, David Brühlmann explores the evolving landscape of biologic manufacturing platforms beyond CHO (Chinese hamster ovary) cells. Drawing from previous interviews with platform pioneers and rigorous dat...
Funding novel therapeutics isn’t just “harder than ever”—the rules have changed entirely. The wild rush of capital into early-stage biotech during 2020–2021 gave way to a drought, making investor priorities sharper and s...
Strong science alone won’t get your biotech startup funded—investors are sizing up much more than just your molecule.Michael Rome, who leads therapeutics investing at Foresite Capital, brings a rare dual lens as both sci...
What happens between scientific discovery and clinical trials? For too many drug candidates, the answer is “failure”—not because the idea lacked merit, but because the critical handoff between discovery and IND-enabling ...
The gap between a “drug” and a true “product” is where many therapies fail.Milan Tomic, biotech veteran, GMP manufacturing expert, and founder of Albrem, has spent 30 years turning promising science into scalable, execut...
The "data lake" that was supposed to unify bioprocessing intelligence has, in most companies, become something else entirely: a data swamp, where information goes in and insight rarely comes back out. For anyone trying t...
When AI can draft a literature review in minutes, the question bioprocess educators can no longer avoid is this: what does a student actually need to learn?Steffen Kreye has a clear answer. As Professor of Industrial Bio...
Can aging be fundamentally slowed or even reversed—not by science fiction, but by harnessing the unassuming power of super-early stem cells?In Part 1, Yuta Lee, Founder and CEO of Accelerated Bio, walked through the biol...
What if the key to scalable, off-the-shelf cell therapy was hiding in tissue that surgeons discard every day?Yuta Lee, Founder and CEO of Accelerated Bio, has spent two decades building a cell therapy platform on exactly...
Are you still using one-factor-at-a-time experiments for biosimilar development, losing months, missing interactions, and risking costly dead-ends?In this episode, David Brühlmann, host of the Smart Biotech Scientist Pod...
Are you stuck screening endless compounds in biosimilar development and still not hitting your quality targets? Efficient compound screening is one of the toughest bottlenecks in biopharma, with outdated methods slowing ...
When every batch belongs to a single patient, a single centralized facility cannot serve the world. In Part 2, Chantale Bernatchez moves from process development into the broader consequences of that reality: the manufac...
The most underappreciated parameter in cell therapy process development is not your bioreactor, your media, or your activation protocol. It is the patient. Chantale Bernatchez has spent 20 years learning that lesson the ...
Getting an NDA signed shouldn't take weeks. If your CRO needs more than 48 hours to start the paperwork, your project timeline is already moving in the wrong direction.Ron Najafi knows what rigorous analytical work actua...
When drug safety fails, patients and entire markets pay the price. Understanding your CMC isn't just compliance — it's the line between therapeutic promise and product recall.Ron Najafi has lived that reality firsthand. ...
Completa el formulario de abajo. Asegúrate de seleccionar tanto País como Géneros.
Envíanos un mensaje abajo. Te responderemos en un plazo de 24 horas.